Part 7. GLUT2 AMG Uptake NGTT2DMNGTT2DM AMG=methyl-  -D-[U 14 C]-glucopyranoside; CPM=counts per minute. Rahmoune H, et al. Diabetes. 2005;54:3427-3434.

Slides:

Advertisements

Similar presentations

Oral Hypoglycemic Drugs And Classifications

Advertisements

Clinical Presentation of Type 2 Diabetes 1. Risk Factors for Prediabetes and Type 2 Diabetes Family history of diabetes mellitus Cardiovascular disease.

Remissione del diabete tipo 2: Terapia Medica Dr. Monica Nannipieri Dipartimento di Medicina Clinica e Sperimentale Università di Pisa.

Treatment Strategies for Diabetes and Obesity: Update 2013 Christopher Sorli, MD/PhD, FACE Chair, Department of Diabetes, Endocrinology and Metabolism.

Diabesity Management Colette Walter, NP. Objectives 1. Pharmacologic management and understanding of treatment related to the overweight diabetic patient.

T2DM MANAGEMENT DENTAL COURSE Mohamed AlMaatouq, MD King Khalid University Hospital King Saud University.

Oral Medications to Treat Type 2 Diabetes

Combination Therapy in Type 2 Diabetes

LONG TERM BENEFITS OF ORAL AGENTS

Therapy of Type 2 Diabetes Mellitus: UPDATE

DIABETES MELLLITUS Strategies for Achieving Control in an Office Setting.

HYPOGLYCEMIC ORAL THERAPY

Conditions associated with insulin resistance

Incretins: Expanding Role in Treatment Strategies Pediatric Type 1 Diabetics (n=8) Insulin dose reduced 20% with exenatide dosing – mixed meal.

Oral Hypoglycemic Drugs

Prevention of Type 2 Diabetes. Hyperglycemia in Type 2 Diabetes: Changing Treatment Paradigms.

Preferred treatment options for patients with Diabetes Dr Jon Tuppen GPwSI Beechwood Surgery Brentwood.

Insulin Pump Debrief. Now that you have worn a Pump… FAQ from people with diabetes Where do I wear this thing? What do I do with it when I play sports?

Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.

Oral hypoglycemic drugs Prof. Mohammad Alhumayyd.

Part 8. Rationale for SGLT2 Inhibitors Inhibit glucose reabsorption in the renal proximal tubule Resultant glucosuria leads to a decline in plasma glucose.

Current Therapy for Type II Diabetes. New ADA Guidelines- 4/20/12 Inzucchi, Diabetologia 4/20/12 SU most prominent- First, reading L to R Added back.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

EXPLAINS Hypoglycemia. EX PLAINS Exogenous Insulin Basal: Lantus Levemir NPH Bolus Novolg Humolog Apidra Regular Exubera(inhaled Insulin )

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.

 GLP-1 agonists have shown to help patients lose weight  Mechanism of GLP-1 agonists  Cardioprotective effects of GLP-1 agonists  GLP-1 agonists and.

Part 10. FPG (mg/dL) BaselineDay 8Day 15 Vehicle (n=6) 0.01 mg/kg (n=6) 0.1 mg/kg (n=6) 1 mg/kg (n=6) 10 mg/kg (n=6) *P

Program Editors Ralph Anthony DeFronzo, MD Professor of Medicine and Chief of the Diabetes Division University of Texas Health Science Center Audie L.

Therapy of Type 2 Diabetes Mellitus: UPDATE

Ralph Anthony DeFronzo, MD

SGLT2 INHIBITION: A NOVEL TREATMENT STRATEGY FOR TYPE 2 DIABETES MELLITUS.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015

Part 1 of 4. Program Editors Ralph Anthony DeFronzo, MD Professor of Medicine and Chief of the Diabetes Division University of Texas Health Science Center.

© 2013 Eli Lilly and Company Managing insulin therapy in Insulin resistance Speaker name and affiliation Prescribing information is available on the last.

Pathophysiology in the Treatment of Type 2 Diabetes Newer Agents Part 3 of 5.

The Obesity/Diabetes Epidemic: Adiposopathy & Obesity- The New Disease! Dx & (Rx) of Insulin Resistance & early DM Stan Schwartz MD, FACP, FACE Private.

Diabetes Mellitus 101 for Cardiologists (and Alike): 2015 Stan Schwartz MD,FACP Affiliate, Main Line Health System Emeritus, Clinical Associate Professor.

Natural History of Type 2 Diabetes Adapted from International Diabetes Center (IDC), Minneapolis, Minnesota. ObesityIFG*DiabetesUncontrolled Hyperglycemia.

Hypoglycemia & Hyperglycemia Dave Joffe, BSPharm, CDE, FACA.

SGLT-2 Inhibitors Surprising New Information. Logic for SGLT-2 Inhibition : My Own Comment on MOA- Logic for Benefit: 1.Kidney is an ‘active player’ in.

Increased Lipolysis Impaired Insulin Secretion TZDs GLP-1 analogues

Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)

Oral Diabetes Medications Carol Cordy, MD. Goals Understand how type 2 diabetes affects many organs and how this changes over the course of the illness.

Therapy for Type II Diabetes. Non-Insulin Therapy for Hyperglycemia in Type 2 Diabetes, Match Patient Characteristics to Drug Characteristics 5. Gut.

Part 5. Insulin Resistance and  -Cell Dysfunction: Summary Individuals with impaired glucose tolerance –Are maximally or near-maximally insulin resistant.

1 Core Defects of Type 2 Diabetes Targeting Mechanisms for a Comprehensive Approach Part 1 1.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions?

6.Fat- increased lipolysis, inc FFA

Treatment of Type 2 Diabetes: Pathophysiology Conclude: do so without Hypoglycemia or Visceral Fat Weight Gain 1.

Pushback What about ‘pure’ Insulin Resistance Syndromes?

Figure 2 Pathophysiology of hyperglycaemia in T2DM

Macrovascular Complications Microvascular Complications

המשותף לכל סוגי הסוכרת היפרגליקמיה כרונית.

SGLT2 Inhibitors and Their Clinical Impact:

EFFICACY AND MECHANISM

Choice of Therapy MYTH: “Most Patients with ‘T2DM’ will eventually

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 3.

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Strategies for the Practical Management of Type 2 Diabetes

Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.

Figure 1 Sites of action of glucose-lowering agents

GLP-1 Agonists and DPP-4 Inhibitors How do they work?

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 7.

Pathophysiology and drug targets.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.

Presentation transcript:

Part 7

GLUT2 AMG Uptake NGTT2DMNGTT2DM AMG=methyl-  -D-[U 14 C]-glucopyranoside; CPM=counts per minute. Rahmoune H, et al. Diabetes. 2005;54: SGLT2 NGTT2DM Normalized Glucose Transporter Levels CPM Increased Glucose Transporter Proteins and Activity in Type 2 Diabetes P<0.05 4

The Ominous Octet Islet  -cell Impaired Insulin Secretion NeurotransmitterDysfunction Decreased Glucose Uptake Islet  -cellIncreased Glucagon Secretion IncreasedLipolysis Increased Glucose Reabsorption IncreasedHGP Decreased Incretin Effect

Lower Posterior Hypothalamus Magnitude of Inhibitory Response (%) ObeseLean P<0.01 Time to Max Inhibitory Response (min) Obese Lean P< Matsuda M, et al. Diabetes. 1999;48: Altered Hypothalamic Function in Response to Glucose Ingestion in Obese Humans

1.Should be based upon known pathogenic abnormalities, and NOT simply on the reduction in HbA 1c 2.Will require multiple drugs in combination to correct multiple pathophysiologic defects 3.Must be started early in the natural history of T2DM, if progressive  -cell dysfunction is to be prevented Treatment of Type 2 Diabetes

DPP-4 Inhibitors Sulfonylureas/ Meglitinides  Treatment of Type 2 Diabetes: A Sound Approach Based Upon Its Pathophysiology Metformin TZDs Metformin  GLP-1 analogues Islet  -cell Impaired Insulin Secretion IncreasedLipolysis Decreased Glucose Uptake IncreasedHGP DPP-4=dipeptidyl peptidase-4.

Years UKPDS Group. Lancet. 1998;352: Median HbA 1c (%) UKPDS: Effect of Glibenclamide and Metformin Therapy on HbA 1c IDF Treatment Goal: <6.5% ConventionalGlibenclamideMetformin

Kahn SE, et al. N Engl J Med. 2006;355: ADOPT: Effect of Glyburide, Metformin, and Rosiglitazone on HbA 1c HbA 1c (%) Years IDF Treatment Goal: <6.5% % (P=0.002) -0.42% (P<0.001) GlyburideMetforminRosiglitazone

Adapted from © 2005 International Diabetes Center, Minneapolis, MN. All rights reserved. Weight Management Type 2 Diabetes Multiple Defects in Type 2 Diabetes Adverse Effects of Therapy Hyperglycemia Unmet Needs in Diabetes Care CVD Risk (Lipid and Hypertension Control)

SGLT2 Inhibition A Novel Treatment Strategy for Type 2 Diabetes

5 mmol/L Fasting Plasma Glucose Muscle  Normal Glucose Homeostasis Fat Liver Pancreas

Fasting Plasma Glucose Pathophysiology of Type 2 Diabetes 10 mmol/L Islet  -cell Impaired Insulin Secretion Insulin Resistance Increased HGP 5 mmol/L